Flatiron Health's Breast Cancer Dataset Hits 1 Million Patients, Expanding Real-World Research Capabilities
Event summary
- Flatiron Health's Breast Cancer Panoramic dataset now includes over 1 million patients, the largest rigorously curated breast cancer real-world dataset.
- The dataset spans the full disease continuum, including 81K+ patients tracked from early to metastatic settings and 840K+ with hormone receptor-positive (HR+) disease.
- Flatiron's real-world evidence has supported applications like NICE recommendations and identifying racial and ethnic inequities in cancer treatment.
- Flatiron offers Panoramic data across 6 million patient records globally, covering solid tumors, hematologic malignancies, and multiple geographies.
The big picture
Flatiron Health's milestone underscores the growing importance of real-world data in oncology research, particularly as biomarker-directed therapies and novel treatment classes become more prevalent. The scale of Flatiron's dataset positions it as a key player in supporting regulatory decisions, commercial strategies, and treatment advancements in breast cancer care. This development also highlights the increasing focus on equity in cancer treatment access and outcomes.
What we're watching
- Data Utilization
- How Flatiron will leverage this expanded dataset to support more personalized treatment decisions and address unmet needs in breast cancer care.
- Regulatory Impact
- Whether the scale and depth of Flatiron's dataset will influence regulatory decisions and approvals for novel breast cancer treatments.
- Market Position
- The pace at which Flatiron can maintain its leadership in real-world data, especially as competitors expand their own datasets and capabilities.